Literature DB >> 9648128

The influence of polypharmacological antidepressive treatment on central nervous information processing of depressed patients: implications for fitness to drive.

H J Grabe1, T Wolf, S Grätz, G Laux.   

Abstract

Antidepressive medication may cause impairment of psychomotor functioning relevant to psychosocial adaptation and fitness to drive. This impairment seems to be less severe by activating antidepressants (SSRI, MAOI). In clinical settings, however, polypharmacological treatment of depressive disorders is frequent. This study evaluates the influence of antidepressants and common comedications on central nervous information processing concerning the ability to drive. Inpatients (n = 44) with major depression (ICD-10) were investigated under steady state plasma level condition. The data were recorded by the Act & React Testsystem ART-90 and analyzed according to medication, severity of illness and age. 88.6% of the patients failed to pass all the tests. With respect to different groups of antidepressants, no differences in psychomotor reaction performance were observed in polydrug treatment. The impact of these results on the patients' fitness to drive is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648128     DOI: 10.1159/000026503

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  3 in total

Review 1.  The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review : 70th Birthday Prof. Riederer.

Authors:  Alexander Brunnauer; Gerd Laux
Journal:  J Neural Transm (Vienna)       Date:  2012-06-09       Impact factor: 3.575

2.  Driving impairment in depressed patients receiving long-term antidepressant treatment.

Authors:  Marleen Wingen; Johannes G Ramaekers; Jeroen A J Schmitt
Journal:  Psychopharmacology (Berl)       Date:  2006-07-25       Impact factor: 4.530

3.  Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies.

Authors:  Alexander Brunnauer; Florian Herpich; Peter Zwanzger; Gerd Laux
Journal:  Int J Neuropsychopharmacol       Date:  2021-09-21       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.